Table 8.
Type of hormonal therapy administered according to menopausal status in 346 pT1a and pT1b tumours
| Premenopausal (N = 89) | Postmenopausal (N = 257) | |
|---|---|---|
|
Hormonal therapy |
|
|
| Tamoxifen 5 y |
11 (12.3%) |
35 (13.6%) |
| Tamoxifen 5 y + LHRH |
65 (73.0%) |
0 (0.0%) |
| Tamoxifen 2-3y→Aromatase Inhibitor 3–2 y |
3 (3.3%) |
44 (17.1%) |
| Aromatase Inhibitor 5 y |
1 (1.1%) |
173 (67.3%) |
| Aromatase Inhibitor 5 y + LHRH |
6 (6.7%) |
1 (0.4%) |
| LHRH alone |
1 (1.1%) |
0 (0.0%) |
| Other | 2 (2.2%) | 4 (1.6%) |